Prognostic Value of Pro-Inflammatory Neutrophils and C-Reactive Protein in Cancer Patient With Coronavirus Disease 2019: A Multi-Center, Retrospective Study

Background: At present, the epidemic of the novel coronavirus disease 2019 (COVID-19) has quickly engulfed the world. Inflammatory cytokines are associated with the severity and outcomes of patients with COVID-19. However, the prognostic value of pro-inflammatory factors in cancer patients with COVID-19 are unknown. Methods: A multi-center, retrospective, cross-sectional study, based on five designated tertiary hospitals for the treatment of COVID-19 in Hubei Province, China. 112 cancer patients with COVID-19, and 105 COVID-19 patients without cancer were enrolled in the study between January 1st, 2020 and April 30th, 2020. The risk assessment of pro-inflammatory factors for disease severity and clinical adverse outcomes was identified by univariable and multivariable logistic regression models. Results: Of the 112 cancer patients with COVID-19, 40 (35.7%) patients were in critical condition and 18 (16.1%) patients died unfortunately. Univariate and multivariate analysis demonstrated that hemoglobin level and pro-inflammatory neutrophils and C-reactive protein (CRP), can be used as independent factors affecting the severity of COVID-19; Meanwhile, pro-inflammatory neutrophils and CRP can be used as an independent influencing factor for adverse clinical outcome of death. Moreover, the dynamic changes of neutrophils and CRP were also presented, and compared with COVID-19 patients without cancer, cancer patients with COVID-19 showed higher neutrophil counts and CRP levels. Conclusion: In cancer patients with COVID-19, the significant increase in pro-inflammatory neutrophils and CRP indicated a more critical illness and adverse clinical outcome, and pro-inflammatory neutrophils and CRP played a greater adverse role compare with COVID-19 patients without cancer, which may be the cause of critical illness and adverse clinical outcomes of cancer patients with COVID-19.

[1]  B. Sahu,et al.  C-reactive protein: A promising biomarker for poor prognosis in COVID-19 infection , 2020, Clinica Chimica Acta.

[2]  Michael R Hamblin,et al.  COVID-19: Transmission, prevention, and potential therapeutic opportunities , 2020, Clinica Chimica Acta.

[3]  Zhenyu Li,et al.  The role of interleukin‐6 in monitoring severe case of coronavirus disease 2019 , 2020, EMBO molecular medicine.

[4]  Shao-bo Shi,et al.  Clinical characteristics and outcomes of cancer patients with COVID‐19 , 2020, Journal of medical virology.

[5]  S. Kalnicki,et al.  Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System , 2020, Cancer discovery.

[6]  M. Santillana,et al.  Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak , 2020, Cancer discovery.

[7]  Carl H. June,et al.  Cytokine release syndrome in severe COVID-19 , 2020, Science.

[8]  Ying Guo,et al.  Association of inflammatory markers with the severity of COVID-19 , 2020, medRxiv.

[9]  J. M. Crawford,et al.  Targeting potential drivers of COVID-19: Neutrophil extracellular traps , 2020, The Journal of experimental medicine.

[10]  Fang Liu,et al.  Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19 , 2020, Journal of Clinical Virology.

[11]  L. Cavanna,et al.  Coronavirus disease-2019 in cancer patients. A report of the first 25 cancer patients in a western country (Italy) , 2020, Future oncology.

[12]  C. Wang,et al.  Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China , 2020, Annals of Oncology.

[13]  T. Guo,et al.  Prognostic value of C-reactive protein in patients with COVID-19 , 2020, medRxiv.

[14]  Li Zhang,et al.  Risk of COVID-19 for patients with cancer , 2020, The Lancet Oncology.

[15]  Huahao Shen,et al.  Risk of COVID-19 for patients with cancer , 2020, The Lancet Oncology.

[16]  Zunyou Wu,et al.  Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. , 2020, JAMA.

[17]  Chuan Qin,et al.  Dysregulation of immune response in patients with COVID-19 in Wuhan, China , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  Ruchong Chen,et al.  Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China , 2020, The Lancet Oncology.

[19]  Yan Zhao,et al.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.

[20]  Ting Yu,et al.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet.

[21]  Jing Zhao,et al.  Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia , 2020, The New England journal of medicine.

[22]  G. Gao,et al.  A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.

[23]  F. Greten,et al.  Inflammation and Cancer: Triggers, Mechanisms, and Consequences. , 2019, Immunity.

[24]  A. Jemal,et al.  Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.

[25]  Michael S. Goldberg,et al.  Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice , 2018, Science.

[26]  V. Papayannopoulos Neutrophil extracellular traps in immunity and disease , 2017, Nature Reviews Immunology.

[27]  P. Kubes,et al.  An emerging role for neutrophil extracellular traps in noninfectious disease , 2017, Nature Medicine.

[28]  A. Jemal,et al.  Cancer statistics in China, 2015 , 2016, CA: a cancer journal for clinicians.

[29]  S. Kakkos,et al.  Patients With Cancer , 2013, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[30]  B. Nordestgaard,et al.  Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer , 2011, Critical reviews in clinical laboratory sciences.

[31]  P. Eckersall,et al.  Evaluation of a rapid assay for canine C-reactive protein , 2004, Veterinary Record.

[32]  B. Hagberg,et al.  CLINICAL CHARACTERISTICS , 1972 .